ImmunoCAP ISAC 112 for multiplex allergen testing (DG24)
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype
Evidence-based recommendations on integrated multiplex polymerase chain tests (xTAG Gastrointestinal Pathogen Panel, FilmArray GI Panel and Faecal Pathogens B
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy
NICE has assessed the procalcitonin tests (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT
Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac
Evidence-based recommendations on faecal immunochemical tests (OC Sensor, HM-JACKarc, FOB Gold and RIDASCREEN) to guide GP referral for colorectal cancer
Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G)
Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical
Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the
Evidence-based recommendations on NIOX MINO, NIOX VERO and NObreath for measuring the amount of exhaled nitric oxide (FeNO) in the breath to help diagnose
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included
Evidence-based recommendations on point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast. The tests are
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
NICE has assessed 3 viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems), to help the NHS decide whether to use these products
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
In development [GID-IP1046] Expected publication date: TBC
In development [GID-IPG10171] Expected publication date: TBC
In development [GID-IPG10172] Expected publication date: TBC
In development [GID-IPG10067] Expected publication date: TBC
In development [GID-IPG10137] Expected publication date: 27 January 2021
In development [GID-IPG10154] Expected publication date: TBC
In development [GID-IP1180] Expected publication date: TBC
In development [GID-IPG10158] Expected publication date: TBC
In development [GID-IPG10159] Expected publication date: TBC
In development [GID-IPG10160] Expected publication date: TBC
In development [GID-IPG10161] Expected publication date: TBC
In development [GID-IPG10163] Expected publication date: TBC
In development [GID-IPG10165] Expected publication date: TBC
In development [GID-IPG10166] Expected publication date: TBC
In development [GID-IPG10181] Expected publication date: TBC
In development [GID-IPG10179] Expected publication date: TBC
In development [GID-IPG10180] Expected publication date: TBC
In development [GID-IP2806] Expected publication date: TBC
In development [GID-IPG10153] Expected publication date: TBC
In development [GID-IP1238] Expected publication date: TBC
In development [GID-IP2803] Expected publication date: TBC
In development [GID-IPG10176] Expected publication date: 27 January 2021
In development [GID-IPG10138] Expected publication date: 03 March 2021
In development [GID-IPG10148] Expected publication date: 03 March 2021
In development [GID-IPG10146] Expected publication date: 03 March 2021
In development [GID-IPG10168] Expected publication date: TBC
In development [GID-IPG10169] Expected publication date: TBC